396 related articles for article (PubMed ID: 21604943)
21. Assays for prostate cancer : changing the screening paradigm?
Hansen J; Rink M; Graefen M; Shariat S; Chun FK
Mol Diagn Ther; 2013 Feb; 17(1):1-8. PubMed ID: 23355098
[TBL] [Abstract][Full Text] [Related]
22. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
23. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.
Sutcliffe P; Hummel S; Simpson E; Young T; Rees A; Wilkinson A; Hamdy F; Clarke N; Staffurth J
Health Technol Assess; 2009 Jan; 13(5):iii, xi-xiii 1-219. PubMed ID: 19128541
[TBL] [Abstract][Full Text] [Related]
24. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
25. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Ulmert D; O'Brien MF; Bjartell AS; Lilja H
Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
[TBL] [Abstract][Full Text] [Related]
26. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
27. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
[TBL] [Abstract][Full Text] [Related]
28. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
[TBL] [Abstract][Full Text] [Related]
29. Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Kristensen G; Berg KD; Lippert S; Christensen IJ; Brasso K; Høyer-Hansen G; Røder MA
J Clin Pathol; 2017 Dec; 70(12):1063-1068. PubMed ID: 28607123
[TBL] [Abstract][Full Text] [Related]
30. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
[TBL] [Abstract][Full Text] [Related]
31. [MOLECULAR MARKERS FOR PROSTATE CANCER].
Engelstein D
Harefuah; 2017 May; 156(5):318-321. PubMed ID: 28551905
[TBL] [Abstract][Full Text] [Related]
32. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Schmid M; Trinh QD; Graefen M; Fisch M; Chun FK; Hansen J
World J Urol; 2014 Aug; 32(4):871-80. PubMed ID: 24825472
[TBL] [Abstract][Full Text] [Related]
33. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T; Haese A; Huland H; Steuber T; Christensen IJ; Brünner N; Danø K; Høyer-Hansen G; Lilja H
Clin Chem; 2006 May; 52(5):838-44. PubMed ID: 16543389
[TBL] [Abstract][Full Text] [Related]
34. Kallikreins as biomarkers for prostate cancer.
Hong SK
Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
[TBL] [Abstract][Full Text] [Related]
35. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
36. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
37. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
38. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
39. Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C
Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411
[TBL] [Abstract][Full Text] [Related]
40. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
